RENBIO
Live / Registered — Registered (as of 28 Jan 2025)
What this means for you
Registered since 28 Jan 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90309237
- Registration number
- 7671681
- Mark type
- Stylized text
- Filed
- 10 Nov 2020
- Published for opposition
- 09 Nov 2021
- Registered
- 28 Jan 2025
- Attorney of record
- Rachelle A. Dubow, Esq.
Goods and services
- Class 001 — Chemicals: Biological products, namely, DNA circle, DNA primers, linear DNA and buffers for use in research and development of pharmaceuticals and for manufacture of pharmaceuticals; Biological products, namely, antibodies, multi-specific antibodies, antibody fragments, proteins, chimeric proteins, drug conjugates and enzymes, for use in research and development of pharmaceuticals and for manufacture of pharmaceuticals
- Class 005 — Pharmaceuticals: Chemical preparations for gene delivery pharmaceuticals for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for therapeutic analysis; biochemical preparations for medical and veterinary purposes, namely, biochemical preparations for gene therapy, for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for gene therapy analysis; Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals for the treatment of genetic or cell based conditions; Pharmaceutical preparations containing nucleic acid sequences that encode monoclonal antibodies for the treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Pharmaceutical compositions for the prevention and treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Biological preparations for the treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Nucleic acid sequences for medical purposes; Pharmaceutical compositions, namely, a nucleotide sequence that encodes an antigen, such as a DNA plasmid having an antigen encoding sequence and like DNA, for the prevention and treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Pharmaceutical preparations for human use for the treatment and prevention of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; pharmaceutical preparations for human and veterinary use, namely, antibiotics, antifungals and anti-virals
- Class 010 — Medical apparatus: Medical apparatus for the administration of biopharmaceuticals and vaccines, namely, drug delivery devices and systems being pulse and waveform generators for the delivery of sub-dermal or intramuscular or intravenous drugs; medical devices, namely, pulse and waveform generators for electroporation mediated administration of drugs to humans and animals; delivery systems comprised of pulse and waveform generators for the delivery of sub-dermal or intramuscular or intravenous drugs for administration of biopharmaceuticals and vaccines for the preventive or treatment of disease in humans and animals; handheld medical systems and devices comprised of pulse and waveform generators using electroporation for the prevention or treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders in humans and animals; handheld clinical delivery systems and devices comprised of pulse and waveform generators for the application of electrical fields in tissue, in particular muscle and skin, in conjunction with the administration of biopharmaceuticals
Owner
- RENBIO, INC., LONG ISLAND CITY, NY, US
- RENBIO, INC., LONG ISLAND CITY, NY, US
- RenBio, Inc., Long Island City, NY, US
- RenBio, Inc., Long Island City, NY, US
Prosecution history
- 28 Jan 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 28 Jan 2025 — REGISTERED-PRINCIPAL REGISTER
- 08 Jan 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 08 Jan 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 07 Jan 2025 — ASSIGNED TO EXAMINER
- 03 Jan 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 18 Dec 2024 — USE AMENDMENT FILED
- 18 Dec 2024 — TEAS STATEMENT OF USE RECEIVED
- 13 Sept 2024 — CORRECTED NOA E-MAILED
- 02 Jul 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Jul 2024 — SOU EXTENSION 5 GRANTED
- 02 Jul 2024 — SOU EXTENSION 5 FILED
- 02 Jul 2024 — SOU TEAS EXTENSION RECEIVED
- 28 Jun 2024 — DIVISIONAL PROCESSING COMPLETE
- 28 Jun 2024 — DIVISIONAL REQUEST RECEIVED